Anthrax continues to pose a significant public health concern due to its potential use as a bioterrorism agent and its ability to cause severe illness in humans. However, this summer a new anthrax vaccine was added to the U.S. arsenal of defense against bioterrorism. On July 20, 2023, the United States Food and Drug Administration (FDA) approved Cyfendus for use in adults aged 18 to 65 years exposed to anthrax.
Learn more and view resources from NETEC about anthrax preparedness.